Skip to search formSkip to main contentSkip to account menu

Napabucasin

Known as: 2-Acetylnaphtho(2,3-b)furan-4,9-dione 
An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

BBI608
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer
ABSTRACT Introduction: Pancreatic cancer (PC) remains a disease with a dismal prognosis. Despite accounting for only 3% of cancer… 
2018
2018
The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and…
4010Background: NAPA is an oral investigational agent, hypothesized to inhibit cancer stemness pathways, including STAT3 pathway… 
2017
2017
CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic…
TPS3619Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and… 
2017
2017
Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).
3529Background: Cancer stem cells are considered to be fundamentally important for resistance, recurrence and metastasis… 
2017
2017
Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC…
593Background: Cancer stem cells or stemness-high cancer cells are considered to be fundamentally important for resistance to… 
2017
2017
CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
TPS4148Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and… 
2017
2017
A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer.
5548Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene… 
2017
2017
A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.
9553Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene… 
2017
2017
BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).
e13525Background: Napabucasin, a first-in-class cancer stemness inhibitor in clinical development, suppresses cancer stemness by… 
2016
2016
A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
9093Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor that works through inhibiting the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)